
zzso zzso zzso a novel zzso zzso that shares a mode of action with the zzso zzso and zzso was active in zzso studies against a broad spectrum of zzso cells and zzso models zzso to zzso and have demonstrated clinical activity in zzso zzso zzso breast cancer zzso zzso The current phase I zzso study sought to define in Japanese patients with advanced solid zzso the maximum tolerated dose zzso and recommended dose zzso of zzso administered as a zzso intravenous infusion every 3 zzso zzso patients were treated in total with 11 of those zzso having previously received a zzso or zzso zzso The zzso was defined as 90 zzso following the occurrence of zzso zzso zzso in two of five patients treated at this dose level including grade 4 zzso lasting zzso days or zzso zzso The zzso for phase II was consequently 75 zzso zzso with no zzso in the six patients zzso The principal toxicity and zzso was zzso with or without zzso zzso zzso responses were reported for 2 of 18 zzso treated patients and a further 8 achieved stable disease zzso The clearance zzso zzso was similar to that observed in Caucasian subjects with value of zzso zzso zzso zzso In conclusion, zzso 75 zzso administered as a zzso infusion every 3 weeks, appeared to be clinically tolerable in this Japanese patient population and showed early indications of zzso 

